 Connection
Holly Lindsay to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Holly Lindsay has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.502 |
|
|
|
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
Score: 0.187
-
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA, Su JM, Xiao S, Erickson SW, Earley EJ, Teicher B, Smith MA, Li XN. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
Score: 0.139
-
Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
Score: 0.121
-
Huang L, Garrett Injac S, Cui K, Braun F, Lin Q, Du Y, Zhang H, Kogiso M, Lindsay H, Zhao S, Baxter P, Adekunle A, Man TK, Zhao H, Li XN, Lau CC, Wong STC. Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Sci Transl Med. 2018 10 24; 10(464).
Score: 0.028
-
Kogiso M, Qi L, Braun FK, Injac SG, Zhang L, Du Y, Zhang H, Lin FY, Zhao S, Lindsay H, Su JM, Baxter PA, Adesina AM, Liao D, Qian MG, Berg S, Muscal JA, Li XN. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin Cancer Res. 2018 05 01; 24(9):2159-2170.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|